COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents aga...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/10/1196 |
| _version_ | 1797513019128807424 |
|---|---|
| author | Hadeel T. Al-Jighefee Hoda Najjar Muna Nizar Ahmed Abeer Qush Sara Awwad Layla Kamareddine |
| author_facet | Hadeel T. Al-Jighefee Hoda Najjar Muna Nizar Ahmed Abeer Qush Sara Awwad Layla Kamareddine |
| author_sort | Hadeel T. Al-Jighefee |
| collection | DOAJ |
| description | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type. |
| first_indexed | 2024-03-10T06:09:48Z |
| format | Article |
| id | doaj.art-bb01b942def84aa888d0daa45c0d4061 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T06:09:48Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-bb01b942def84aa888d0daa45c0d40612023-11-22T20:16:46ZengMDPI AGVaccines2076-393X2021-10-01910119610.3390/vaccines9101196COVID-19 Vaccine Platforms: Challenges and Safety ContemplationsHadeel T. Al-Jighefee0Hoda Najjar1Muna Nizar Ahmed2Abeer Qush3Sara Awwad4Layla Kamareddine5Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, QatarDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, QatarDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, QatarDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, QatarDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, QatarDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, QatarThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type.https://www.mdpi.com/2076-393X/9/10/1196SARS-CoV-2COVID-19vaccine platformschallengessafetystrengths |
| spellingShingle | Hadeel T. Al-Jighefee Hoda Najjar Muna Nizar Ahmed Abeer Qush Sara Awwad Layla Kamareddine COVID-19 Vaccine Platforms: Challenges and Safety Contemplations Vaccines SARS-CoV-2 COVID-19 vaccine platforms challenges safety strengths |
| title | COVID-19 Vaccine Platforms: Challenges and Safety Contemplations |
| title_full | COVID-19 Vaccine Platforms: Challenges and Safety Contemplations |
| title_fullStr | COVID-19 Vaccine Platforms: Challenges and Safety Contemplations |
| title_full_unstemmed | COVID-19 Vaccine Platforms: Challenges and Safety Contemplations |
| title_short | COVID-19 Vaccine Platforms: Challenges and Safety Contemplations |
| title_sort | covid 19 vaccine platforms challenges and safety contemplations |
| topic | SARS-CoV-2 COVID-19 vaccine platforms challenges safety strengths |
| url | https://www.mdpi.com/2076-393X/9/10/1196 |
| work_keys_str_mv | AT hadeeltaljighefee covid19vaccineplatformschallengesandsafetycontemplations AT hodanajjar covid19vaccineplatformschallengesandsafetycontemplations AT munanizarahmed covid19vaccineplatformschallengesandsafetycontemplations AT abeerqush covid19vaccineplatformschallengesandsafetycontemplations AT saraawwad covid19vaccineplatformschallengesandsafetycontemplations AT laylakamareddine covid19vaccineplatformschallengesandsafetycontemplations |